timing is impossible to predict, we could wake up tomorrow to an acquisition and $40+, or some unexpected bad news could tank the stock. Development stage biotech is a #$%$ shoot. ACAD looks like a good bet. I am sure BB's have done a ton of DD, they have a major investment, so unless they start selling...I am staying long, but there's no guarantee that Pima will be approved, will sell, will work in other indications...
I think it's best to wait for the full study, this was just one MD, 30 ppl. I think the potential is huge, but who knows if the trial will replicate the results. Also, he used half of the Belviq dose, which is interesting for several reasons. The actual trial uses 2x daily, which could lead to higher side effects. If only half a dose is needed, that might have a negative effect on demand, but that could certainly be overcome with much higher usage. Anyway since this was not a full trial, best to be safe and wait.
I see the short crooks are at work punishing the new buyers.
Apologies, after reading a story from the IV board, I see Sandra was a problem fixer at Genzyme, so a rare good hire by IMGN. As another IV board poster stated, "good hire, now let's get rid of some of the dead wood."
I read many stories on the IV board that seem far more material than IMGN hiring another exec. This company is the most top-heavy, non-productive company with no successful phase II trials in the history of biotech. Genzyme has a history of significant mfg/production quality issues, it's not the first company I would search for manufacturing talent.
He said ADP could be a $BB in the US alone and then if approved for other indications sales could eventually reach $5BB, or something to that effect. Depending on pipelines, prospects for growth, biotech equities are typically valued at about 4-6X sales. So, at x5 valuation could reach in the $25BB range, or about 10x the current price. That would be years away and if everything works out well. I would take $40 this year (before approval), or $50+ shortly after the drug is approved. Anything else is probably too low considering the potential. All IMO.
That was very aggressive and obviously a long way out in time, but it may have caught some large pharma's attention and certainly caught the shorts by surprise. It's better to have Cramer's backing than not.
what was the sample size and average BMI? Did they exercise, or just take the drugs? Was there a placebo, or comparison group? Thanks.
you can bet he's receiving something for his efforts, these people don't do any work for free. IMO of course.
Pasting from FierceBiotech article this morning:
The label is also likely to crimp sales of Contrave, a combination of naltrexon and bupropion. "The effect of Contrave on cardiovascular morbidity and mortality has not been established," patients are warned. The drug is tied to higher blood pressure rates and, because it includes bupropion, includes a harsh warning on potential neuropsychiatric side effects. The FDA notes that the label includes "a boxed warning to alert healthcare professionals and patients to the increased risk of suicidal thoughts and behaviors associated with antidepressant drugs."
On Thursday Novo Nordisk will face a panel of outside agency experts who will review its application of liraglutide 3 mg, a higher dose of a GLP-1 drug that is approved as Victoza for diabetes and represents a major effort on the Danish pharma company to tackle one of the chief causes of diabetes.
I speculate they were hired to help the shorts out of their massive short position. DF shows a long position, but I doubt they are really net long. Did Jack help them? He's given them overly favorable deals in the past. Do they own Jack? Why is Cindy in Switzerland. Very strange happenings here, but maybe ARNA is reaching a point of deep value. The question is if/or when the shareholders will reap any rewards. Probably not before the shorts exit. IMO and pure speculation.